person · Reporting owner

Wysenski Nancy

Disclosed activity across 6 companies

Tapewire entity: 16754
SEC CIK: 0001294596

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	July 07, 2023	July 11, 2023
CYTOKINETICS INCCYTK · Entity 3528	Director	July 15, 2026	July 16, 2026
TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285	Director	June 10, 2019	June 11, 2019
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	EVP, Chief Commercial Officer	May 14, 2012	June 01, 2012

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date July 07, 2023 · Filed July 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	20,356	Ending reported balance After 2023-07-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-07-07 · Exercise / conversion · Acquired 5,957 · Balance 21,786 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2023-07-07 · Tax withholding · Disposed 1,430 · Balance 20,356
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-07-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-07-07 · Exercise / conversion · Disposed 5,957 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms.
Ordinary SharesSEC Table I · non-derivative	IndirectThe Nancy J. Wysenski Revocable Trust	11,242	Reported balance Holding disclosure · report date 2023-07-07 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,242 F2: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust").

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust").

F3: This award is fully vested in accordance with its terms.

CYTOKINETICS INC

Report date July 15, 2026 · Filed July 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,992	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 75 · Balance 33,992 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

TETRAPHASE PHARMACEUTICALS INC

Report date June 10, 2019 · Filed June 11, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2029-06-09	Direct	16,500	Reported balance After 2019-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-10 · Grant · Acquired 16,500 · Balance 16,500 F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.

VERTEX PHARMACEUTICALS INC / MA

Report date May 14, 2012 · Filed June 01, 2012 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	32,232	Last balance in matching sequence After 2012-05-14 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2012-05-14 · Sale · Disposed 179,628 · Balance 32,604 F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82). F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 2 · 2012-05-14 · Sale · Disposed 372 · Balance 32,232 F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.

Filing footnotes · ownership attribution and instrument terms

F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.

F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82).

F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Disposition to issuer · Disposed 6,274 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.36 · Expires 2029-04-25	Direct	0	Reported balance After 2019-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.

F2: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Provention Bio, Inc.

Report date April 27, 2023 · Filed April 27, 2023

Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.16	Direct	Reported balance After 2023-04-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-04-27 · Disposition to issuer · Disposed 128,981 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.62	Direct	Reported balance After 2023-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-04-27 · Disposition to issuer · Disposed 22,200 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80	Direct	Reported balance After 2023-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-04-27 · Disposition to issuer · Disposed 23,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.52	Direct	Reported balance After 2023-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-04-27 · Disposition to issuer · Disposed 33,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.

F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 02, 2021 Filed Dec 4, 2021 02:29 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	5,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-030305 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
October 01, 2021 Filed Oct 4, 2021 23:04 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	153	$36.74	$5,621.22	Disclosure SEC source: 0001061983-21-000233 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,881 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021. F2 · balance_after: Amount includes 881 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
July 07, 2021 Filed Jul 8, 2021 21:32 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	31	$19.77	$612.87	Disclosure SEC source: 0001061983-21-000192 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,728 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.77, representing the Issuer's closing stock price on July 7, 2021. F2 · balance_after: Amount includes 728 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
July 01, 2021 Filed Jul 2, 2021 22:01 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	238	$20.98	$4,993.24	Disclosure SEC source: 0001061983-21-000176 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021. F2 · balance_after: Amount includes 697 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:30 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	7,585	$0.00	$0.00	Disclosure SEC source: 0001127602-21-020049 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. Read SEC document
June 14, 2021 Filed Jun 16, 2021 20:30 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	15,677	$0.00 Strike: $24.72	$0.00	Disclosure SEC source: 0001127602-21-020049 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,677 Underlying: Ordinary Shares · 15,677 shares Expires 2031-06-14 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/14/2022. Read SEC document
May 20, 2021 Filed May 21, 2021 20:41 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	6,104	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-017792 · form4.xml · derivative · entry 4 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This restricted stock unit award vested in full on 5/20/2021. F2 · derivative.expiration_date: This restricted stock unit award vested in full on 5/20/2021. Read SEC document
May 20, 2021 Filed May 21, 2021 20:41 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,404	$21.92	$30,775.68	Disclosure SEC source: 0001127602-21-017792 · form4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Read SEC document
May 20, 2021 Filed May 21, 2021 20:41 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	6,104	$0.00	$0.00	Disclosure SEC source: 0001127602-21-017792 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 12, 2021 Filed May 14, 2021 00:04 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $24.32	$0.00	Disclosure SEC source: 0001061983-21-000146 · edgardoc.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-12 F3 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022. Read SEC document
May 12, 2021 Filed May 14, 2021 00:04 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001061983-21-000146 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,459 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022. F2 · balance_after: Amount includes 459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
May 12, 2021 Filed May 14, 2021 19:57 UTC	Provention Bio, Inc. PRVB · Entity 12101	GrantStock Option (right to buy) · Derivative	23,000	$0.00 Strike: $6.80	$0.00	Disclosure SEC source: 0001493152-21-011599 · ownership.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock, par value $0.0001 · 23,000 shares Expires 2031-05-12 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 12, 2022. Read SEC document
April 01, 2021 Filed Apr 5, 2021 21:48 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	204	$24.44	$4,985.76	Disclosure SEC source: 0001061983-21-000101 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $24.44, representing the Issuer's closing stock price on April 1, 2021. F2 · balance_after: Amount includes 459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
January 04, 2021 Filed Jan 5, 2021 23:19 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	255	$19.56	$4,987.80	Disclosure SEC source: 0001061983-21-000018 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021. F2 · balance_after: Amount includes 255 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
December 02, 2020 Filed Dec 4, 2020 21:39 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,578	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-030583 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,578 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. Read SEC document
December 02, 2020 Filed Dec 4, 2020 21:39 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	11,509	$0.00 Strike: $18.82	$0.00	Disclosure SEC source: 0001127602-20-030583 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,509 Underlying: Ordinary Shares · 11,509 shares Expires 2030-12-02 F1 · derivative.exercise_date: This option becomes exercisable in full on 12/2/2021. Read SEC document
November 20, 2020 Filed Nov 20, 2020 23:43 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (right to buy) · Derivative	35,000	$15.99 Strike: $15.99	$559,650.00	Disclosure SEC source: 0001061983-20-000179 · edgardoc.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-11-20 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 35,000 shares divided into equal monthly installments with the first vesting installment on December 20, 2020 and the final vesting installment on November 20, 2023. Read SEC document
July 15, 2020 Filed Jul 16, 2020 18:01 UTC	Provention Bio, Inc. PRVB · Entity 12101	GrantOption (right to buy) · Derivative	22,200	$0.00 Strike: $12.62	$0.00	Disclosure SEC source: 0001493152-20-013475 · ownership.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,200 Underlying: Common Stock, par value $0.0001 · 22,200 shares Expires 2030-07-15 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 22,200 option shares vest on July 15, 2021. Read SEC document
May 20, 2020 Filed May 22, 2020 20:26 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	6,104	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-017779 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. Read SEC document
May 20, 2020 Filed May 22, 2020 20:26 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	12,823	$0.00 Strike: $16.85	$0.00	Disclosure SEC source: 0001127602-20-017779 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,823 Underlying: Ordinary Shares · 12,823 shares Expires 2030-05-20 F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021. Read SEC document
May 19, 2020 Filed May 21, 2020 16:06 UTC	Provention Bio, Inc. PRVB · Entity 12101	GrantStock Option (right to buy) · Derivative	128,981	$0.00 Strike: $13.16	$0.00	Disclosure SEC source: 0001493152-20-009624 · ownership.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Underlying: Common Stock, par value $0.0001 · 128,981 shares Expires 2030-05-19 F1 · derivative.exercise_date: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. The option vests in eight equal semi-annual installments commencing on November 19, 2020 and will become fully vested on May 19, 2024. Read SEC document
February 24, 2020 Filed Feb 25, 2020 22:15 UTC	Alkermes plc. ALKS · Entity 2392	PurchaseOrdinary Shares	6,940	$19.65	$136,371.00	Disclosure SEC source: 0001127602-20-007701 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Nancy J. Wysenski Revocable Trust Disclosed balance after: 11,242 F1 · ownership.nature: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust"). Read SEC document
November 12, 2019 Filed Nov 12, 2019 16:41 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $9.36	Not disclosed	Disclosure SEC source: 0001209191-19-056046 · doc4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-04-25 F2 · price: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. F2 · derivative.exercise_date: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. Read SEC document
November 12, 2019 Filed Nov 12, 2019 16:41 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	Disposition to issuerCommon Stock	6,274	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-056046 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. F1 · price: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. Read SEC document
June 10, 2019 Filed Jun 11, 2019 23:22 UTC	TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285	GrantStock Option (right to buy) · Derivative	16,500	$0.00 Strike: $0.77	$0.00	Disclosure SEC source: 0001209191-19-036262 · doc4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2029-06-09 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document
May 22, 2019 Filed May 23, 2019 22:39 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	22,400	$0.00 Strike: $25.04	$0.00	Disclosure SEC source: 0001127602-19-019718 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,400 Underlying: Ordinary Shares · 22,400 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/22/2020. Read SEC document
April 26, 2019 Filed Apr 30, 2019 16:33 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $9.36	$0.00	Disclosure SEC source: 0001209191-19-026571 · doc4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-04-25 F1 · derivative.exercise_date: Vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document
March 14, 2019 Filed Mar 18, 2019 21:05 UTC	Alkermes plc. ALKS · Entity 2392	PurchaseOrdinary Shares	445	$33.06	$14,711.70	Disclosure SEC source: 0001127602-19-011890 · form4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Nancy J. Wysenski Revocable Trust Disclosed balance after: 4,302 F2 · ownership.nature: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust"). Read SEC document
February 21, 2019 Filed Mar 18, 2019 21:05 UTC	Alkermes plc. ALKS · Entity 2392	PurchaseOrdinary Shares	3,857	$33.09	$127,628.13	Disclosure SEC source: 0001127602-19-011890 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Nancy J. Wysenski Revocable Trust Disclosed balance after: 3,857 F1 · date: Late filing due to administrative error. F2 · ownership.nature: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust"). Read SEC document
February 05, 2019 Filed Feb 7, 2019 16:55 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	GrantCommon Stock	6,274	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-008108 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,274 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document
June 25, 2018 Filed Jun 26, 2018 16:59 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $33.47	$0.00	Disclosure SEC source: 0001209191-18-039514 · doc4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: One-third (1/3) of the total shares subject to the option shall vest on June 25, 2019 and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over two years, subject to the Reporting Person's continuous service through such vesting date Read SEC document
May 30, 2018 Filed Jun 1, 2018 20:18 UTC	TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $3.68	$0.00	Disclosure SEC source: 0001209191-18-034670 · doc4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-29 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document
May 23, 2018 Filed May 24, 2018 22:29 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $45.64	$0.00	Disclosure SEC source: 0001127602-18-018856 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2028-05-23 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/23/19. Read SEC document
May 31, 2017 Filed Jun 1, 2017 21:04 UTC	TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $6.89	$0.00	Disclosure SEC source: 0001209191-17-036845 · doc4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-30 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document
May 24, 2017 Filed May 25, 2017 22:06 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	14,200	$0.00 Strike: $58.25	$0.00	Disclosure SEC source: 0001127602-17-019451 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Ordinary Shares · 14,200 shares Expires 2027-05-24 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/24/18. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	3,398	$0.00 Strike: $38.80	$0.00	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · derivative · entry 10 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,383 Underlying: Common Stock · 3,398 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	25,000	$0.00 Strike: $39.70	$0.00	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · derivative · entry 9 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 25,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	147,071	$0.00 Strike: $39.70	$0.00	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · derivative · entry 8 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,929 Underlying: Common Stock · 147,071 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	4,531	$0.00 Strike: $37.86	$0.00	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · derivative · entry 7 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,969 Underlying: Common Stock · 4,531 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	372	$65.00	$24,180.00	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · nonDerivative · entry 6 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,232 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	179,628	$64.27	$11,544,691.56	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · nonDerivative · entry 5 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,604 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	3,398	$38.80	$131,842.40	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · nonDerivative · entry 4 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	25,000	$39.70	$992,500.00	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · nonDerivative · entry 3 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	147,071	$39.70	$5,838,718.70	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed May 16, 2012 20:33 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	4,531	$37.86	$171,543.66	Disclosure SEC source: 0001209191-12-028591 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2012 Filed Jun 1, 2012 21:08 UTC Amendment	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	372	$65.00	$24,180.00	Disclosure SEC source: 0001209191-12-031713 · doc4a.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,232 F1 · kind: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. Read SEC document
May 14, 2012 Filed Jun 1, 2012 21:08 UTC Amendment	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	179,628	$64.27	$11,544,691.56	Disclosure SEC source: 0001209191-12-031713 · doc4a.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,604 F1 · kind: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. F2 · price: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
May 08, 2012 Filed May 9, 2012 20:40 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	18,750	$0.00 Strike: $39.70	$0.00	Disclosure SEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 18 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Underlying: Common Stock · 18,750 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 08, 2012 Filed May 9, 2012 20:40 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	10,196	$0.00 Strike: $38.80	$0.00	Disclosure SEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 17 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,781 Underlying: Common Stock · 10,196 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 08, 2012 Filed May 9, 2012 20:40 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option · Derivative	9,063	$0.00 Strike: $33.82	$0.00	Disclosure SEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 16 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,390 Underlying: Common Stock · 9,063 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.